Hydroxyapatite crystal formation in dental enamel

Hydroxyapatite crystal formation in dental enamel is not a single defined molecule, protein, enzyme, or receptor, but rather a biomineralization process in which calcium and phosphate ions organized by enamel matrix proteins (notably amelogenin, enamelin, tuftelin) form highly ordered crystals of carbonated hydroxyapatite within the developing tooth enamel[1][2][3][5]. This process occurs via a complex, stepwise pathway: initial amorphous calcium phosphate (ACP) precursors are stabilized by proteins, then gradually transform into oriented hydroxyapatite crystals as the enamel matures[2][5]. Amelogenin and related proteins regulate crystal shape, spacing, and organization; disruptions in this process can lead to enamel defects but the formation event itself is not a druggable target or conventional molecular entity[1][2][5][6]. Notes: - This entry describes a process (biomineralization/crystal formation), not a discrete molecular target suitable for traditional pharmacological or biomarker classification. - Several proteins (e.g., amelogenin, enamelin, tuftelin) and ions (Ca²⁺, PO₄³⁻) are molecular participants, but the process as a whole is not a single target. - No drugs act directly on the process of "hydroxyapatite crystal formation"—instead, agents like fluoride affect enamel mineralization indirectly by altering the chemistry favoring fluorapatite, which is more acid-resistant[4].

N/A - This is a biological process, not a conventional drug target. Fluoride indirectly influences mineralization by promoting fluorapatite formation, which is more acid-resistant.